MediWound to Present at Oppenheimer 25th Annual Healthcare Conference

Oppenheimer Healthcare Conference 2014

YAVNE, Israel--()--MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that Company management will participate at the Oppenheimer 25th Annual Healthcare Conference taking place from December 10-11, 2014 in New York City. Gal Cohen, President and Chief Executive Officer of MediWound, will be presenting a corporate overview on Thursday, December 11th at 3:20 p.m. Eastern time.

Mr. Cohen’s presentation will broadcast live and can be accessed by visiting the investors section of the company’s website at www.mediwound.com. A replay of the webcast will be archived on the MediWound website for 90 days following the presentation.

About MediWound Ltd.

MediWound is a fully integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, as well as chronic and other hard-to-heal wounds. MediWound’s first innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency for removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns and has been launched in Europe. NexoBrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and, without harming viable tissues. For more information, please visit www.mediwound.com.

Contacts

MediWound Ltd.
Sharon Malka
Chief Financial & Operation Officer
ir@mediwound.co.il
or
LHA
Anne Marie Fields, 212-838-3777
Senior Vice President
afields@lhai.com

MediWound Ltd.